StockDriftsStockDriftsTop 3 Medicxi Ventures Management (Jersey) Ltd Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| PHAT | PHATHOM PHARMACEUTICALS INC | 45.65% | 7.46M | $81.0M | +0.00%(+0) | $15.94(-46.00%) | 2026-06-30 | |
| NAMS | NEWAMSTERDAM PHARMA COMPANY | 42.19% | 2.21M | $74.9M | -17.41%(-465.54K) | $11.08(+153.20%) | 2026-06-30 | |
| AURA | AURA BIOSCIENCES INC | 12.16% | 3.04M | $21.6M | +0.00%(+0) | $16.98(-55.59%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | +14.44% | +49.86% | +8.06% | +47.33% |
| Top 20 Holdings Unweighted | +20.12% | +73.31% | +23.68% | +189.45% |
Medicxi Ventures Management (Jersey) Ltd reports $177.42M in US-listed equity holdings across 3 positions in its most recent 13F filing. Its largest disclosed positions are PHAT (45.6%), NAMS (42.2%) and AURA (12.2%). The top 20 holdings account for 100% of reported assets. Its disclosed equity book has returned +49.86% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Medicxi Ventures Management (Jersey) Ltd, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Medicxi Ventures Management (Jersey) Ltd’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1715579). View Medicxi Ventures Management (Jersey) Ltd’s 13F filings on SEC